Cangrelor

Trade names

KENGREAL

Actions

• Reversible P2Y12 receptor antagonist.

Route of Administration

Intravenous

Bioavailability

100%

Plasma protein binding

~97-98%

Time to peak plasma concentration

Seconds

Time to plasma steady state

Seconds

Half-life

2–5 min

Elimination

Renal ~58%, biliary ~35%

Duration of action

60 min

Reversible platelet inhibition

Yes

Recommended dose

30 μg/kg bolus followed by intravenous infusion of 4 μg/kg/min.

Indicated as adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications.

Renal impairment

No dose adjustment is necessary.

Discontinuation before invasive procedures

1–6 h